Barbara Kollerits

Introduction Chronic kidney disease (CKD) affects more than 10% of the global population, constituting a public health burden with medical and financial implications [1]. CKD is defined by a decreased kidney function with a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 or by kidney damage for more than 3 months [1, 2]. Even mild forms of CKD are associated with adverse clinical outcomes, particularly of a cardiovascular nature [1, 3, 4].

Discussion To the best of our knowledge, this is the largest prospective study that has examined PCSK9 concentrations and outcomes in a cohort of high-risk participants with moderate CKD. The main findings are as follows. (1) PCSK9 concentrations are not associated with kidney function parameters, such as eGFR or UACR (except a slight increase in participants with nephrotic-range albuminuria).

PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function Azin Kheirkhah, Claudia Lamina, Barbara Kollerits, Johanna Schachtl-Riess, Ulla Schultheiss, Lukas Forer, Peggy Sekula, Fruzsina Kotsis, Kai-Uwe Eckardt, Florian Kronenberg CJASN Apr 2022, CJN.01230122; DOI: 10.2215/CJN.01230122